Loading stock data…
PFE
$26.70+0.44 (+1.68%)
Market ClosedLast close Apr 30
Pfizer Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pfizer Inc. in the Healthcare sector is trading at $26.70. The stock is currently 7% below its 52-week high of $28.75, remaining 5.9% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why PFE maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHABBV
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.70
Potential Upside
4%
Whystock Fair Value$27.76
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$29.00+8.6%
Range$24.00 – $36.00
Fundamentals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$152.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.71
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Strong income play. Yield provides a meaningful total return floor.
630.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.43%
Volume
Today's trading volume
39.03M
Recent News
Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multiple myeloma drug.
OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...
Despite revenue setbacks, OPKO Health Inc (OPK) shows resilience with strategic advancements and a strong cash position.
AWS CEO Matt Garman sees huge business opportunity for Amazon in AI-powered software: ‘Everything is going to be remade’
In an interview with Fortune, the CEO of Amazon Web Services discussed the company’s new push into productivity software as well as its partnership with OpenAI.
Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the 10 Stocks Reeling From Huge Losses. Relay Therapeutics dropped for a second day on Tuesday, slashing 12.84 percent to finish at $13.03 apiece, as investors appeared to have taken profits after already jumping by 74 percent this month, thanks to positive data from its cancer treatment candidate, […]